Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma

This study evaluated the cost effectiveness of bortezomib in relapsed, refractory myeloma, relative to best supportive care (BSC) and thalidomide. Data were derived from the phase 2 pivotal study of bortezomib, a Delphi panel of six myeloma thought leaders, and published literature. Objective assump...

Full description

Saved in:
Bibliographic Details
Published inManaged care interface Vol. 17; no. 9; p. 52
Main Authors Mehta, Jayesh, Duff, Steven B, Gupta, Sanjay
Format Journal Article
LanguageEnglish
Published United States 01.09.2004
Subjects
Boronic Acids - adverse effects
Boronic Acids - economics
Boronic Acids - therapeutic use
Bortezomib
Cost-Benefit Analysis
Delphi Technique
Economics, Pharmaceutical
Female
Humans
Male
Middle Aged
Multiple Myeloma - drug therapy
Pyrazines - adverse effects
Pyrazines - economics
Pyrazines - therapeutic use
Thalidomide - administration & dosage
Treatment Outcome
Online AccessGet more information

Cover

More Information
Summary:This study evaluated the cost effectiveness of bortezomib in relapsed, refractory myeloma, relative to best supportive care (BSC) and thalidomide. Data were derived from the phase 2 pivotal study of bortezomib, a Delphi panel of six myeloma thought leaders, and published literature. Objective assumptions regarding treatment choices and consequences (response and complications), and actual cost data were used. Bortezomib was found to be cost effective relative to BSC and thalidomide. Sensitivity analyses demonstrated the robustness of the results. These data suggest that bortezomib provides a cost-effective treatment option and the best value (in terms of cost/life-yr gained) among the currently available therapeutic options for relapsed, refractory myeloma.
ISSN:1096-5645